The U.S. Food and Drug Administration is expected to announce today, July 24, 2026, whether it will approve centanafadine, a new medication for attention-deficit/hyperactivity disorder that works through a mechanism no currently approved ADHD drug uses. If approved, centanafadine would become the first treatment in an entirely new pharmacological class for ADHD, offering a new route for patients who have struggled with stimulants or found existing non-stimulant options insufficient.
The announcement, due under the Prescription Drug User Fee Act timeline the FDA accepted in January 2026, is among the most anticipated drug decisions in the attention and neurodevelopmental space in years. For the estimated 15.5 million adults and 7 million children and adolescents diagnosed with ADHD in the United States, the outcome carries direct treatment consequences.
